Predictions
UnitedHealth Group Inc.
Start price
Target price
Perf. (%)
€503.00
13.12.23
13.12.23
€538.32
13.12.24
13.12.24
7.85%
06.09.24
06.09.24
McDonalds Corp.
Start price
Target price
Perf. (%)
€268.70
12.12.23
12.12.23
€315.11
12.12.24
12.12.24
-1.12%
06.09.24
06.09.24
Procter & Gamble Co.
Start price
Target price
Perf. (%)
€135.12
11.12.23
11.12.23
-
11.01.24
11.01.24
1.55%
12.01.24
12.01.24
Market Leader or Top 3
Nike Inc. B
Start price
Target price
Perf. (%)
€109.30
11.12.23
11.12.23
-
11.01.24
11.01.24
-10.75%
02.01.24
02.01.24
Standard Investments for future growth
Valuable balance sheet
Growths faster than the competition
Medium risks for its business
Nike Inc. B
Start price
Target price
Perf. (%)
€72.73
11.12.23
11.12.23
-
11.01.24
11.01.24
-
11.12.23
11.12.23
Standard Investments for future growth
Valuable balance sheet
Growths faster than the competition
Medium risks for its business
Exxon Mobil Corp.
Start price
Target price
Perf. (%)
€92.09
08.12.23
08.12.23
€118.20
08.12.24
08.12.24
13.23%
06.09.24
06.09.24
McDonalds Corp.
Start price
Target price
Perf. (%)
€266.50
07.12.23
07.12.23
€310.75
07.12.24
07.12.24
-0.30%
06.09.24
06.09.24
McDonalds Corp.
Start price
Target price
Perf. (%)
€266.00
07.12.23
07.12.23
€301.41
07.12.24
07.12.24
-0.12%
06.09.24
06.09.24
JPMorgan Chase & Co.
Start price
Target price
Perf. (%)
€144.30
07.12.23
07.12.23
€166.00
07.12.24
07.12.24
34.94%
06.09.24
06.09.24
Top 10 in its market
Known brand
Future proof or reliable business model
Pfizer Inc.
Start price
Target price
Perf. (%)
€26.80
07.12.23
07.12.23
-
07.12.24
07.12.24
0.50%
06.09.24
06.09.24
Small challenges to pay loans and raise capital
Innovative
Very small cyclical dependencies
Some uniques
International Business Machines Corp
Start price
Target price
Perf. (%)
€150.15
05.12.23
05.12.23
€157.57
05.12.24
05.12.24
23.69%
06.09.24
06.09.24
Apple Inc.
Start price
Target price
Perf. (%)
€199.24
05.12.23
05.12.23
-
05.01.24
05.01.24
-
05.12.23
05.12.23
Could be very worthwhile Investment >20% year
Revenue growth > 30% per year expected
Very high dividend yield expected
EBIT growth > 30% per year expected